Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models-Reference-Cited by-同舟云学术

Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models

Published:2013-08-05 Issue:8 Volume:8 Page:e71754
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Li Zhimin,Qiu Yushi,Personett David,Huang Peng,Edenfield Brandy,Katz Jason,Babusis Darius,Tang Yang,Shirely Michael A.,Moghaddam Mehran F.,Copland John A.,Tun Han W.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference18 articles.

1. How I treat primary CNS lymphoma;AJ Ferreri;Blood,2011

2. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model;FJ Hernandez-Ilizaliturri;Clin Cancer Res,2005

3. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation;D Zhu;Cancer Immunol Immunother,2008

4. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype;FJ Hernandez-Ilizaliturri;Cancer,2011

5. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases;S Camilleri-Broët;Blood,2006

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis;Journal of Clinical Neuroscience;2024-06

2. Targets and treatments in primary CNS lymphoma;Leukemia & Lymphoma;2024-04-24

3. Exploring the binding mechanism of Pomalidomide drug with CT-DNA: Insights from multi-spectroscopic, molecular docking and simulation studies;Journal of Molecular Structure;2024-04

4. Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease;Blood Science;2024-03-01

5. Identification of CYFIP2 Arg87Cys Ligands via In Silico and In Vitro Approaches;Biomedicines;2024-02-21